TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14535873
Drug: Omeprazole 2
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 2 x 20 mg with clarithromycin 2 x 250 mg and metronidazole 2 x 400 mg
Study: 8937280
Drug: Benznidazole (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole (7.5 mg/kg daily for 60 days)
Study: 8299527
Drug: lisinopril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril (5 mg/d, sometimes increased to 10 mg/d after 3 weeks)
Study: 8299527
Drug: captopril (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (twice daily 12.5 mg, sometimes increased to twice 25 mg after 3 weeks)
Study: 28320259
Drug: Levosimendan (0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.025 to 0.2 μg/kg/min continuous infusion)
Study: 21964228
Drug: Multisensory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisensory stimulation (MSS) program, 55 minutes, twice a week for 10 weeks
Study: 16573792
Drug: Low cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low cholesterol diet (300 mg/day)
Study: 16573792
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol diet (1300 mg/day)
Study: 11270020
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of propofol
Study: 30820338
Drug: Bolus administration
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus administration of propofol
Study: 11008222
Drug: Ribavirin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribavirin (600 mg/day for 8 weeks, followed by 1,000 mg/day for 8 weeks, and then 1,200 mg/day for 8 weeks)
Study: 1568523
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg cefetamet pivoxil twice daily (n = 18)
Study: 1568523
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg cefetamet pivoxil twice daily (n = 8)
Study: 1568523
Drug: 30-50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-50 mg/kg amoxycillin/clavulanic acid three times daily (n = 11)
Study: 29550566
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg daily (4 weeks on/2 weeks off)
Study: 27865358
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg monacolin K from RYR and 200 μg folic acid per day
Study: 19438927
Drug: Monosodium glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate (MSG) 75 mg/kg
Study: 27091318
Drug: Monosodium glutamate
Normalized name: Monosodium Glutamate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monosodium glutamate (MSG) 150 mg/kg
Study: 19438927
Drug: NaCl (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (24 mg/kg, placebo)
Study: 7812004
Drug: Conventional G‐banding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional G‐banding method
Study: 7032828
Drug: Guanfacine (1‐‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanfacine (1‐‐5 mg daily)
Study: 7032828
Drug: Post-treatment placebo
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment placebo period
Study: 7032828
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of guanfacine
Study: 24005134
Drug: Levobupivacaine hydrochloride
Normalized name: Levobupivacaine Hydrochloride
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaine hydrochloride (5 mL, chirocaine 25 mg/10 mL) soaked PVA sponge
Study: 24005134
Drug: Saline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (5 mL) soaked PVA sponge
Study: 19435690
Drug: S-GemOx (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-GemOx (gemcitabine 1,000 mg/m2, 100-minute infusion D1 followed by oxaliplatin 100 mg/m2, 120-minute infusion)
Study: 16963671
Drug: Montelukast, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 10 mg/d for 8 weeks
Study: 11407865
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone alone or together with glutamine with or without a low-fat diet containing high-carbohydrate (fibre)
Study: 7960545
Drug: Lymphoscintigraphy using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoscintigraphy using colloid agents labelled with gold and technetium (99mTc‐pertechnetate)
Study: 18636354
Drug: Somatostatin combined
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin combined with oral vancomycin
Study: 16549021
Drug: Seal oil
Normalized name: seal oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seal oil administration (n-3 polyunsaturated fatty acid rich seal oil)
Study: 16549021
Drug: Soy oil
Normalized name: Hydrogenated soy oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy oil administration (n-6 fatty acid rich)
Study: 11151866
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of erythromycin i.v.
Study: 11151866
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg of i.v. ondansetron (serotonin receptor antagonist) pretreatment
Study: 8466682
Drug: Zidovudine 500
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 500 mg per day (group A)
Study: 8466682
Drug: Zidovudine 1000
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine 1000 mg per day (group B)
Study: 3541414
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg isosorbide dinitrate (ISDN, once-daily) plus 120 mg verapamil (t.i.d.)
Study: 3541414
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg isosorbide dinitrate (ISDN, once-daily) plus 80 mg propranolol (b.i.d.)
Study: 3541414
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all three drugs (ISDN, verapamil, propranolol)
Study: 22992762
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of bisphosphonate treatment at two weeks after the operation (Group I, n = 24)
Study: 22992762
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of bisphosphonate treatment at three months (Group II, n = 26)
Study: 11873025
Drug: Ropivacaine 0.17%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.17%, 14 ml, administered epidurally during the diurnal period (morning and afternoon)
Study: 11873025
Drug: Ropivacaine 0.17%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.17%, 14 ml, administered epidurally during the nocturnal period (night and evening)
Study: 10350384
Drug: Dirithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (500 mg od for 5 days)
Study: 10350384
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg qid for 7 days)
Study: 7858733
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous growth hormone (GH) for 5 months
Study: 6132524
Drug: Acebutol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutol (400 to 800 mg daily)
Study: 6132524
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 to 400 mg daily)
Study: 30998402
Drug: Suture-Spanning Augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suture-Spanning Augmentation of Single-Row Repair (SSA-SR)
Study: 22800876
Drug: Financial reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial reinforcement interventions (longer duration, $50 or more per week, at least weekly reinforcement)
Study: 17578312
Drug: Liqi Kuanxiong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liqi Kuanxiong Huoxue method (LKH) in addition to conventional treatment
Study: 17578312
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (nitrate, diltiazem hydrochloride, etc.)
Study: 15224278
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab (group II)
Study: 15224278
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg infliximab at weeks 2 and 6, followed by 10 mg/kg thereafter (group III)
Study: 12044534
Drug: Interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2b (6 MU three times per week for 24 weeks followed by 3 MU three times per week for 24 weeks) in combination with ribavirin for 48 weeks (group B)
Study: 12044534
Drug: Daily interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interferon alpha‐2b (3 MU per day for 24 weeks followed by 3 MU three times per week for 24 weeks) and ribavirin (group C)
Study: 12044534
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with three times weekly interferon and ribavirin
Study: 12044534
Drug: Daily interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interferon and ribavirin
Study: 8123947
Drug: Heparin 500
Normalized name: HEPARIN 5000 UNT/ML SYRINGE 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 500 units and Hydrocortisone 10 mg/L
Study: 8123947
Drug: In-line filter
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-line filter with drug-free infusate
Study: 8123947
Drug: Long intravenous
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long intravenous catheters (30 cm)
Study: 8123947
Drug: Short intravenous
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short intravenous catheters
Study: 2700316
Drug: Whole liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole liver radiation therapy (RT) alone
Study: 2700316
Drug: Whole liver
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole liver radiation therapy (RT) combined with chemotherapy (systemic and/or intra-hepatic)
Study: 2700316
Drug: Innovative techniques
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovative techniques of delivering RT (intraoperative brachytherapy, radiolabeled antibodies, hyperfractionated external beam RT)
Study: 15726550
Drug: Paracetamol up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol up to 3 g/d
Study: 15726550
Drug: Aspirin up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin up to 3 g/d
Study: 15726550
Drug: Ibuprofen up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen up to 1200 mg/d
Study: 12238905
Drug: Terbutaline (Bricanyl,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (Bricanyl, 5.0 mg/2ml)
Study: 12238905
Drug: Fenoterol (Berotec,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (Berotec, 1.25 mg/2ml)
Study: 9620106
Drug: Antifungal prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifungal prophylaxis (systemic, intranasal, lipid formulations of amphotericin B, fluconazole, itraconazole)
Study: 7865418
Drug: Rubber dam
Normalized name: Aspergillus ruber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubber dam isolation and mechanical preparation of pits and fissures using a round bur No. 0 in a slow hand‐piece
Study: 7865418
Drug: Cotton rolls
Normalized name: Cotton
DrugBank: Cotton (DB10707)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotton rolls isolation and mechanical preparation of pits and fissures using a round bur No. 0 in a slow hand‐piece
Study: 31289040
Drug: Nivolumab and
Normalized name: nivolumab and relatlimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab and ipilimumab (perioperative immunotherapy)
Study: 28682837
Drug: Semiautonomous (decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semiautonomous (decision assist) fluid administration
Study: 22848080
Drug: Blockade day
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blockade day (combined oral H(1) and H(2) receptor antagonism with fexofenadine and ranitidine)
Study: 19226297
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl (Group Fv)
Study: 12486749
Drug: Selective exclusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective exclusion of treatment arms in multi-arm randomized clinical trials
Study: 9987698
Drug: Modafinil 600
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 600 mg
Study: 9987698
Drug: Modafinil 800
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil 800 mg
Study: 8749241
Drug: Domperidone 20
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 20 mg orally
Study: 8749241
Drug: Metoclopramide 20
Normalized name: metoclopramide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 20 mg as suppository or 10‐20 mg orally
Study: 8749241
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg acetylsalicylic acid as effervescent tablets
Study: 8749241
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg paracetamol as effervescent tablets or suppositories
Study: 8749241
Drug: Naproxen 500-1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500-1,000 mg
Study: 8749241
Drug: Ibuprofen 400-800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400-800 mg
Study: 8749241
Drug: Standard reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard reference drugs
Study: 2080867
Drug: Intranasal interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal interferon alpha-2a
Study: 7351286
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg prostaglandin E2 three times daily
Study: 31811429
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) for patients with nodal grouping (NG) in stages N1 and N2
Study: 31152080
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 intravenously every 3 weeks) plus Prednisone (5 mg twice daily) plus Cediranib (30 mg once daily)
Study: 31152080
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m2 intravenously every 3 weeks) plus Prednisone (5 mg twice daily)
Study: 19624286
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation containing PLC, L‐Arg and nicotinic acid (Ezerex)
Study: 19624286
Drug: Vardenafil (Levitra)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vardenafil (Levitra) 20 mg twice a week
Study: 19624286
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation plus vardenafil 20 mg twice a week
Study: 19624286
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules twice weekly
Study: 15291499
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of fresh Sweetie juice
Study: 15291499
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of fresh Sweetie juice
Study: 9459232
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg after surgery (Group D)
Study: 9459232
Drug: ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 4 mg before induction (Group C)
Study: 9459232
Drug: ondansetron 2
Normalized name: ondansetron 24 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 2 mg at the start of and 2 mg after surgery (Group B)
Study: 26137850
Drug: Herbal compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal compound containing Malva sylvestris and Alcea digitata (Boiss)
Study: 11404758
Drug: Gold alloy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold alloy with chamfer finish line (group G)
Study: 9423503
Drug: Routine Treatment
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine Treatment (RT) group
Study: 3115130
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (SCG) nasal spray
Study: 3115130
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of sodium cromoglycate and hyposensitization
Study: 29897544
Drug: 2-g LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-g LP bar (11 g protein with 2 g added LP)
Study: 29897544
Drug: 3-g LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-g LP bar (13 g protein with 3 g added LP)
Study: 29897544
Drug: 0-g LP
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0-g LP bar (9 g protein with 0 g added LP)
Study: 22493913
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy during dog days and the three nine‐day periods after the winter solstice (Group A)
Study: 22493913
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy during dog days (Group B)
Study: 22493913
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy during the three nine‐day periods after the winter solstice (Group C)
Study: 15890634
Drug: Dextromethorphan (DEX)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DEX) 60 mg
Study: 15890634
Drug: Dextromethorphan (DEX)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DEX) 90 mg
Study: 12753447
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 micro g.kg‐1 i.v.
Study: 10593672
Drug: Methylprednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1 mg/kg daily for 10 days orally)
Study: 17712121
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg/d
Study: 8732960
Drug: Sibutramine 15
Normalized name: sibutramine 15 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 15 mg/d
Study: 8732960
Drug: Sibutramine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 20 mg/d
Study: 8732960
Drug: Sibutramine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 30 mg/d
Study: 22344575
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/week
Study: 29036790
Drug: Endostar combined
Normalized name: Menostar
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endostar combined with NP chemotherapy
Study: 29036790
Drug: NP chemotherapy
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP chemotherapy alone (Control)
Study: 26445179
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (100 mL 3 times daily)
Study: 26445179
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (100 mL 3 times daily)
Study: 26445179
Drug: Water (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (100 mL 3 times daily)
Study: 19445546
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CBT plus sertraline
Study: 19445546
Drug: Fluvoxamine 25
Normalized name: fluvoxaMINE 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 25 mg/day, Fluoxetine 10 mg/day, Sertraline 25 mg/day
Study: 19445546
Drug: Pharmacotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy with systematic tracking of treatment-emergent adverse events
Study: 19445546
Drug: Long-term medication
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term medication use
Study: 15623680
Drug: Petasites extract
Normalized name: Petasites fragrans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petasites extract 75 mg bid
Study: 15623680
Drug: Petasites extract
Normalized name: Petasites fragrans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Petasites extract 50 mg bid
Study: 9203933
Drug: Omeprazole 60
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole 60 mg/day for three days and 80 mg intravenous before perfusion
Study: 9203933
Drug: Ranitidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 600 mg/day for three days and 50 mg/h intravenous during perfusion
Study: 3308483
Drug: Single five-drug
Normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single five-drug combination (adriamycin 50 mg, vincristine 1.5 mg, 5-fluorouracil 750 mg intravenously; methotrexate 50 mg intramuscularly; chlorambucil 10 mg orally, followed by three doses of chlorambucil 10 mg at 6-h intervals)